Given the known resistance mechanisms of MEK inhibition in colorectal cancer, we hypothesized that tumors with known KRAS/NRAS or BRAF mutations that were PIK3CA wild-type would exhibit greater sensitivity to MEK inhibition [13]. Here, MAP2K7 is linked to colorectal cancer.